Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced ...

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it developed a Research Use Only (RUO) molecular PCR test, via its subsidiary TIB MOLBIOL, for use on the LightCycler® 480 I & II Systems, ...
mccormick.northwestern.edu

Monkeypox Rapid PCR Test in Development

Last spring, a rapid polymerase chain reaction (PCR) test for COVID-19 — developed by Northwestern University spinoff company Minute Molecular Diagnostics — received emergency use authorization (EUA) ...
pharmaphorum

Roche develops Bundibugyo Ebola test in six days

A PCR diagnostic developed by Roche for the Bundibugyo form of Ebola is being offered to health systems at the front lines of ...
Medical Device Network on MSN

Roche develops RUO PCR assay to detect rare Ebola Bundibugyo virus

TIB MOLBIOL developed the test using its "rapid response" library, with 15,000 designs and 3,000 controls.
Phys.org

A 5-minute PCR, faster than self-diagnosis kits

PCR technology is a molecular diagnostics technology that detects target nucleic acids by amplifying the DNA amount. It has brought marked progress in the life sciences field since its development in ...